Improved tumor identification using dual tracer molecular imaging in fluorescence guided brain surgery

Xiaochun Xu; Veronica Torres; David Straus; Eric M. Brey; Richard W. Byrne; Kenneth M. Tichauer

doi:10.1117/12.2076305

Translator Disclaimer

4 March 2015 Improved tumor identification using dual tracer molecular imaging in fluorescence guided brain surgery

Xiaochun Xu, Veronica Torres, David Straus, Eric M. Brey, Richard W. Byrne, Kenneth M. Tichauer

Author Affiliations +

Proceedings Volume 9311, Molecular-Guided Surgery: Molecules, Devices, and Applications; 93110O (2015) https://doi.org/10.1117/12.2076305
Event: SPIE BiOS, 2015, San Francisco, California, United States

Abstract

Brain tumors represent a leading cause of cancer death for people under the age of 40 and the probability complete surgical resection of brain tumors remains low owing to the invasive nature of these tumors and the consequences of damaging healthy brain tissue. Molecular imaging is an emerging approach that has the potential to improve the ability for surgeons to correctly discriminate between healthy and cancerous tissue; however, conventional molecular imaging approaches in brain suffer from significant background signal in healthy tissue or an inability target more invasive sections of the tumor. This work presents initial studies investigating the ability of novel dual-tracer molecular imaging strategies to be used to overcome the major limitations of conventional “single-tracer” molecular imaging. The approach is evaluated in simulations and in an in vivo mice study with animals inoculated orthotopically using fluorescent human glioma cells. An epidermal growth factor receptor (EGFR) targeted Affibody-fluorescent marker was employed as a targeted imaging agent, and the suitability of various FDA approved untargeted fluorescent tracers (e.g. fluorescein & indocyanine green) were evaluated in terms of their ability to account for nonspecific uptake and retention of the targeted imaging agent. Signal-to-background ratio was used to measure and compare the amount of reporter in the tissue between targeted and untargeted tracer. The initial findings suggest that FDA-approved fluorescent imaging agents are ill-suited to act as untargeted imaging agents for dual-tracer fluorescent guided brain surgery as they suffer from poor delivery to the healthy brain tissue and therefore cannot be used to identify nonspecific vs. specific uptake of the targeted imaging agent where current surgery is most limited.

Citation Download Citation

Xiaochun Xu, Veronica Torres, David Straus, Eric M. Brey, Richard W. Byrne, and Kenneth M. Tichauer "Improved tumor identification using dual tracer molecular imaging in fluorescence guided brain surgery", Proc. SPIE 9311, Molecular-Guided Surgery: Molecules, Devices, and Applications, 93110O (4 March 2015); https://doi.org/10.1117/12.2076305

ACCESS THE FULL ARTICLE